Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heartburn relief in a pill? PepZinGI put to the test

NCT ID NCT07379645

Symptom relief Sponsor: NutriScience Innovations, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether PepZinGI, a zinc-L-carnosine supplement, can reduce heartburn triggered by food. Fifty adults with frequent heartburn completed two one-week treatment periods (PepZinGI and placebo) remotely, using wearable devices and surveys to track symptoms and sleep. The goal is to see if this supplement offers a simple, over-the-counter option for managing occasional heartburn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PepZinGI (zinc-L-carnosine)
What this could lead to
If it works, this could offer a natural supplement option for occasional heartburn relief.
What could go wrong
This is a small, early-stage trial with only 50 participants. Results may not apply to everyone, and the supplement may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jan 2026

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥21 years * Self-reported food-triggered heartburn with known trigger foods * Heartburn at least once per week * Willing to avoid OTC/supplement heartburn treatments during study (calcium-carbonate rescue allowed but must be logged and not used during hurdle-meal day/night) * Able to complete electronic surveys and adhere to procedures * Access to or willingness to use a compatible wearable device Exclusion Criteria: * Clinician-diagnosed GERD, UC, Crohn's, or IBD * Prescribed drugs for heartburn/digestive conditions * Heartburn less than once per week or daily throughout the month * More than 1 alcoholic drink/day on average during study * Recreational drug use during study * Known allergy to zinc, L-carnosine, or study ingredients * Pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heartburn are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease Heartburn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heartburn

Contacts and locations

Locations

  • Alethios, Inc

    San Francisco, California, 94104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.